Use of cd2/5/7 knock-out Anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias
A chimeric antigen receptor, leukemia technology, applied to anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, receptor/cell surface antigen/cell surface determinant, NGF-receptor/TNF-receptor It can solve the problems of T-cell lymphoma and leukemia, such as poor prognosis, few treatment methods, and CART cells cannibalism.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0478] Example 1: A new approach to targeting T-cell lymphoma and leukemia without causing T-cell toxicity
[0479] The overall prognosis of T-cell lymphomas and leukemias is very poor, and few treatment options are available for these patients. Chimeric antigen receptor T-cell (CART) immunotherapy has achieved unprecedented results in CD 19+ B-cell non-Hodgkin's lymphoma (B-NHL). Herein, another successful "CART19-like" product was designed to target T-NHL. Since CD19 is not expressed in T-NHL, other targets such as CD2, CD5, CD7, etc. were evaluated for CART therapy. However, all of these targets are also expressed by normal T cells, leading to unacceptable clinical toxicity (T cell agenesis-immunodeficiency) ( figure 1 ). Herein, a safe and effective CART strategy for the treatment of T-cell lymphoma was developed by editing normal T cells resistant to CART killing ( figure 2 ). CART therapy against T-cell lymphomas and leukemias is feasible when CART targets (CD2, ...
Embodiment 2
[0480] Example 2: Anti-CD5 CAR T cells (CART5) and CD5 knockout (KO) normal T cells
[0481] This paper discloses a two-pronged immunotherapy comprising anti-CD5 CAR T cells (CART5) and CD5 knockout (KO) normal T cells ( image 3 ). CART5 destroys T-cell lymphoma (such as T-NHL) or T-cell leukemia cells, but also kills normal T cells. Infusion of CD5 KO normal T cells provides CART resistant T cell immunity until CART5 cells are depleted, in some cases by use of suicide genes (eg iCasp9, CD20 / rituximab or others).
[0482]CD5 was chosen as a T-NHL target due to its high expression on T-NHL cells and its lack of expression in tissues other than T cells and a small subset of B cells. Single chain variable fragments (scFv) with different affinities (#17, #34, #9 with high, medium and low affinity respectively (Klitgaard JL, et al. (2013) British journal of haematology 163:182-93)) were used ) generated six anti-CD5 CAR constructs and expressed them in T cells ( Figure 4-5 ...
Embodiment 3
[0503] Example 3: Anti-CD2 CAR T cells (CART2) and CD2 knockout (KO) normal T cells
[0504] This paper discloses a two-pronged approach to immunotherapy comprising anti-CD2 CAR T cells (CART2) and CD2 knockout (KO) normal T cells ( image 3 ). CART2 destroys T-cell lymphoma (such as T-NHL) or T-cell leukemia cells, but also kills normal T cells. Infusion of CD2 KO normal T cells provided CART-resistant T cell immunity until CART2 cells were depleted, in some cases through the use of suicide genes (eg iCasp9).
[0505] Guide RNAs were designed to knock down the CD2 gene (and CD5) using the CRISPR / Cas9 system. CD2 was efficiently knocked out in 78% of the T cell population. Second-generation anti-CD2 and anti-CD5 CARs (CART2 and CART5, respectively) were generated ( Figure 4 ). Knockout cells (CD2KO and CD5KO) were incubated with their corresponding CART cells (CART2 and CART5, respectively), stimulated and measured for population doubling ( Figure 7 ). Mock electrop...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com